Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

Experimental Hematology & Oncology

Xinwei Han¹  Anping Li¹  Weiheng Zhao²  Kongming Wu²  Shengnan Yu²  Shuang Qin²  Qian Liu² 

[1] Department of Interventional Radiology, First Affiliated Hospital of Zhengzhou University;Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology;

关键词: HER2;    Trastuzumab;    Pertuzumab;    T-DM1;    Bispecific antibody;    Ertumaxomab;   

DOI  :  10.1186/s40164-017-0091-4

来源: DOAJ

【 摘 要 】

Abstract HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for the treatment of HER2 positive metastatic breast cancer. The combined application of pertuzumab, trastuzumab and paclitaxel has been suggested as a standard therapy for HER2 positive advanced breast cancer. The resistance to anti-HER2 antibody has resulted in disease progression. HER2-directed bispecific antibody may be a promising therapeutic approach for these patients. Ertumaxomab enhanced the interaction of immune effector cells and tumor cells. MM-111 simultaneously binds to HER2 and HER3 and blocks downstream signaling. Besides, HER2Bi-aATC is also an alternative therapeutic approach for HER2 positive cancers. In this review, we summarized the recent advancement of HER2-targeted monoclonal antibodies (trastuzumab, pertuzumab and T-DM1) and bispecific antibodies (MM-111, ertumaxomab and HER2Bi-aATC), especially focus on clinical trial results.

【 授权许可】

Unknown